Block listing Interim Review

Induction Healthcare Group PLC
29 January 2024
 

 

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

 

Block Listing Six Monthly Return

 

Induction Healthcare (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 

Name of applicant:

Induction Healthcare Group PLC

 

LEI: 213800RY96GCZQW5TP19

 

Name of scheme:

The Induction Healthcare NTA Share Option Plan

 

Period of return:

 

 From:

27/07/2023

To:

27/01/2024

 

Number and class of securities originally admitted and the date of admission

 

3,500,000 ordinary shares on 26 July 2021

Balance of unallotted securities under scheme(s) from initial application:

 

3,500,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

 

nil

Less: Number of securities issued/allotted under scheme(s) during the period:

 

1,469,075

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

 

1,701,352

Contact:

Louise Torr, Company Secretary

louise.t@inductionhealthcare.com






 

ENQUIRIES

 

Induction Healthcare Group

Christopher Samler, Chair

Paul Tambeau, Chief Executive Officer

 

+44 (0)7712 194092

+44 (0)7983 104443

 

 

 

 

Singer Capital Markets (Nominated Adviser and Broker)

+44 (0)20 7496 3000

 

Philip Davies

 

 

 

 

 

 

 

About Induction - www.inductionhealthcare.com

 

Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

 

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings